The Novo Nordisk Foundation Center for Basic Metabolic Research > Research > Metabolic Genetics > Scientific Director Pr...
Scientific Director Oluf Borbye Pedersen
MD, Dr Med Sci, Professor and specialist- authorized in endocrinology and internal medicine.
Curriculum Vitae of Oluf Borbye Pedersen
Director at Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, University of Copenhagen, Denmark (DK) (www.metabol.ku.dk); Professor of Molecular Metabolism and Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen.
Education, Authorization, Clinical Career, University Faculties and International Academic Training
Medical Doctor (MD), University of Aarhus, DK (1972); Doctor of Medical Science (Dr Med), University of Aarhus (1983); Danish Health Board-authorised Specialist of Internal Medicine (1987) and Specialist of Endocrinology (1987); Chief Physician and Research Director at Steno Diabetes Centre and Hagedorn Research Institute, Copenhagen, a leading European and WHO-collaborative diabetes centre (1989 – 2010); Professor of Molecular Diabetology at the Faculty of Health Sciences, University of Copenhagen (Personal Chair) (1995-2000); from 2001- a similar appointment at University of Aarhus; Professor of Molecular Metabolism at University of Copenhagen (from 2008-); Professor of Metabolic Genetics, University of Copenhagen (from 2010-); Visiting Professorships at Harvard Medical School, Boston (2 yrs), and Peking Union Medical College and Beijing Genomics Institute (1.5 yrs).
Leadership and Academic Supervision
Extensive leadership experiences with multidisciplinary clinical and basic research teams at Steno Diabetes Centre and Hagedorn Research Institute; Founder and Director of Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care (www.lucamp.org) (2007-2013) - an international research centre of excellence with partners from all Danish Universities, Berkeley University, California and Beijing Genomics Institute, Shenzhen; since 2010 head of Section of Metabolic Genetics, Novo Nordisk Foundation Centre for Basic Metabolic Research; university supervisor for 43 research fellows who have achieved their doctor of medicine (Dr. Med.) or their PhD degrees and for 50 master students.
Research Innovation and Impact
Development of state-of-the-art methods for isolation of human fat cells and novel methods for accurate measurement of polypeptide hormone binding and action in human adipocytes which have become standard within the field; first demonstration that physical contraction stimulates translocation of GLUT4 in skeletal muscle through a mechanism distinct from that of insulin; identification and characterization of multiple intermediary metabolic phenotypes associated with validated genetic variants of common cardio-metabolic traits through in-depth genetics-physiology and genetics-epidemiology studies; conduction of a pioneering large-scale whole exome sequencing study (2,000 exomes) with massive genotyping follow-up in up to 70,000 Europeans to identify low-frequency gene variants associated with common cardio-metabolic traits; as a partner in the EU-Metahit initiative (www.metahit.eu) delivered contributions to the first metagenome-sequencing-driven gut microbial catalogue of 3.3 mio bacterial genes and the discovery of a new biological fingerprint: gut enterotypes; setting of new standards for the care of type 2 diabetes patients on the basis of findings from the Steno-2 Study: a randomized landmark trial comparing the effects of an intensive multifactorial intervention with that of conventional treatment on angiopathy in high-risk patients with type 2 diabetes. The study demonstrated that 8 years of intensive intervention with multiple drug combinations and behaviour modification cuts the risk of micro-and macrovascular complications by half. Similarly, a follow-up assessment 13 years later showed a 50% reduction in overall mortality. The outcome of this first-in class structured multifactorial and whole patient care approach has had critical implications for the care of diabetes patients worldwide.
Author of > 600 scientific reports: 510 peer-reviewed original scientific papers and 96 scientific reviews or textbook chapters; Web of Knowledge Bibliometrics; total citations 22,618; h-index: 72.
International and National Scientific Network Development and Engagement
During recent years hold principal investigator (PI) partnerships in 7 EU-financed research consortia and 15 long-term research initiatives sponsored by the Danish Research Councils or private Danish research foundations; active partner in development of international scientific networks with the focus on human genetics, e. g. deCODE genetics, DIAGRAM, MAGIC, EGG, Beijing Genetics Institute (BGI), Shenzhen, Lund University, Turku University, Pasteur Institute in Lille and Imperial College in London, Oxford University, Michigan University, Berkeley University, BROAD Institute in Boston, more Universities in New Delhi and Chennai, Peking Union Medical College, Chinese-Japanese Friendship Hospital, Beijing and Tokyo University.
Recognition and Offices of Honour
Received recognition including 14 international and national personal awards; president and chair of the Danish Diabetes Association (1995-2000) – a NGO with about 70,000 members and a professional staff of 35; services as chairman or member on boards of scientific societies, biomedical councils, grant bodies and scientific journals.
Declaration of potential conflicts of interests
Project grant support
Dr. Pedersen and his team of investigators have, together with allocation of competitive research grants from national and international public or private grant bodies obtained unrestricted research grants from pharmaceutical industries, primarily Novo Nordisk.
Lecture- and consulting fees
Oluf Pedersen reports receiving travel-, congress- lecture- or consulting fees from Glaxo-Smith-Kline, Servier, Sanofi-Aventis, Astra Zeneca, Bayer, Tethys Bioscience and Eli Lilly.
Equity and royalty
Oluf Pedersen reports an equity interest in Novo Nordisk A/S and receipt of royalty fees from medical and scientific textbooks.
Oluf Borbye Pedersen, Professor, MD, DMSCi, Novo Nordisk Foundation Center for Basic Metabolic Research, DIKU, Universitetsparken 1, Copenhagen, Denmark
Phone: PA Grete Lademann +45 3533 7122 or +45 3533 7121